Exparel is an injectable medication used for the treatment of post-surgical pain [1]. It is a non-opioid local anesthetic that provides targeted pain relief [2].
How does Exparel work to manage pain?
Exparel contains the active ingredient bupivacaine [1]. It is formulated with proprietary multivesicular liposome technology, which allows for the extended release of bupivacaine over time [3]. This sustained release mechanism means Exparel can provide pain control for up to 72 hours after a single administration, unlike traditional bupivacaine injections which have a shorter duration of action [4]. The liposomes encapsulate the bupivacaine and gradually release it as the liposome structure degrades [3].
What surgical procedures is Exparel approved for?
Exparel is indicated for intercostal nerve block for thoracic surgery, surgical site infiltration for bunionectomy, এছাড়াও [1], total knee arthroplasty [5], and total hip arthroplasty [6].
What are the potential side effects of Exparel?
Common side effects reported with Exparel include constipation and nausea [1]. In clinical trials, patients also experienced headache, fever, and vomiting [2]. Serious adverse events are rare and can include nerve injury or damage at the injection site, potentially leading to temporary or permanent loss of feeling or movement [1].
How does Exparel compare to other pain management options?
As a non-opioid, Exparel offers an alternative to opioid analgesics, which carry risks of addiction, respiratory depression, and other side effects [2]. Its extended-release formulation provides prolonged pain relief from a single dose, potentially reducing the need for repeated administrations of shorter-acting anesthetics or systemic pain medications [4].
When does Exparel's patent protection expire?
Information regarding the specific patent expiration dates for Exparel is available through specialized patent tracking resources [7]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate when market exclusivity is expected to end [7].
Can generic versions of Exparel be developed?
The development of generic versions of Exparel would depend on patent expirations and regulatory pathways. For complex formulations like Exparel, generic manufacturers would need to demonstrate bioequivalence, and the process can be influenced by the patent landscape and any existing exclusivities [7].